Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | B2M L13fs B2M LOH |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| B2M L13fs B2M LOH | melanoma | predicted - resistant | Ipilimumab | Case Reports/Case Series | Actionable | In a clinical case study, B2M loss of heterozygosity (LOH) and L13fs were identified as acquired mutations in one lineage of resistant tumor cells in a melanoma patient whose disease progressed on Yervoy (ipilimumab) treatment, B2M LOH and L13fs were also identified in the pre-treatment biopsy of a melanoma patient who did not respond to Yervoy (ipilimumab) treatment (PMID: 29070816). | 29070816 | |
| B2M L13fs B2M LOH | melanoma | predicted - resistant | Pembrolizumab | Case Reports/Case Series | Actionable | In a clinical case study, a melanoma patient with acquired B2M loss of heterozygosity (LOH) and L13fs did not respond to Keytruda (pembrolizumab) treatment (PMID: 29070816). | 29070816 |